These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17571381)

  • 1. [Omapatrilat for treatment of heart failure].
    Yamazaki T
    Nihon Rinsho; 2007 May; 65 Suppl 5():173-5. PubMed ID: 17571381
    [No Abstract]   [Full Text] [Related]  

  • 2. Omapatrilat.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
    Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
    Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure].
    Heinzl S
    Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study.
    Solomon SD; Skali H; Bourgoun M; Fang J; Ghali JK; Martelet M; Wojciechowski D; Ansmite B; Skards J; Laks T; Henry D; Packer M; Pfeffer MA;
    Am Heart J; 2005 Aug; 150(2):257-62. PubMed ID: 16086927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new class of potent antihypertensive agents. Especially systolic pressure is significantly reduced].
    MMW Fortschr Med; 1999 Nov; 141(47):8. PubMed ID: 10912157
    [No Abstract]   [Full Text] [Related]  

  • 9. [Vasopeptidase inhibition: a new mechanism of action--a new antihypertensive drug].
    Waeber B
    Praxis (Bern 1994); 2000 Apr; 89(16):649-53. PubMed ID: 10823018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
    Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
    Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopeptidase inhibitors in heart failure.
    Dawson A; Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2002 Sep; 3(3):156-9. PubMed ID: 12563565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopeptidase inhibitors--concepts and evidence.
    Ruschitzka F; Corti R; Quaschning T; Hermann M; Lüscher TF
    Nephrol Dial Transplant; 2001 Aug; 16(8):1532-5. PubMed ID: 11477147
    [No Abstract]   [Full Text] [Related]  

  • 14. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasopeptidase inhibition and angio-oedema.
    Messerli FH; Nussberger J
    Lancet; 2000 Aug; 356(9230):608-9. PubMed ID: 10968427
    [No Abstract]   [Full Text] [Related]  

  • 16. Update of ELITE-II, BEST, CHAMP, and IMPRESS clinical trials in heart failure.
    Witte K; Thackray S; Banerjee T; Clark AL; Cleland JG
    Eur J Heart Fail; 2000 Mar; 2(1):107-12. PubMed ID: 10742710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
    Nathisuwan S; Talbert RL
    Pharmacotherapy; 2002 Jan; 22(1):27-42. PubMed ID: 11794428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of stress and behavioral interventions in hypertension: the rise and fall of omapatrilat.
    Pickering TG
    J Clin Hypertens (Greenwich); 2002; 4(5):371-3. PubMed ID: 12368583
    [No Abstract]   [Full Text] [Related]  

  • 19. [Heart failure and vasopeptidase inhibitors].
    Bareiss P; Ohlmann P; Roul G
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):51-3. PubMed ID: 11933558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent clinical trials with omapatrilat: new developments.
    Zanchi A; Maillard M; Burnier M
    Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.